Drug Trial Radar · NCT01929512
Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 750mg and Rosuvastatin 20mg
Last checked: Nov 19, 2026Latest source record: Aug 30, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Jun 2013
Primary completion
Aug 2013
Study completion Aug 2013
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Aug 28, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 20 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To compare the pharmacokinetic characteristics between HCP1201 tablet 750/20 mg and co-administration of metformin 750 mg plus rosuvastatin 20 mg under fasted and fed state, respectively.
Conditions
- Diabetes Mellitus
Interventions
HCP1201 750/20mgDrug
750mg Metformin/20mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
Metformin SR 750mgDrug
Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
Rosuvastatin 20mgDrug
Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
Primary outcomes
What the sponsor says the trial is designed to measure.
- metformin, rosuvastatin CmaxTime frame: pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h
- metformin, rosuvastatin AUClastTime frame: pre-dose, post-dose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 48 h
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Samsung Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.